First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

Martin Reck, Tudor–Eliade Ciuleanu, Jong Seok Lee, Michael Schenker, Clarisse Audigier-Valette, Bogdan Żurawski, Helena Linardou, Gregory A. Otterson, Pamela Salman, Makoto Nishio, Emmanuel de la Mora Jimenez, Krysztof Lesniewski-Kmak, István Albert, Samreen Ahmed, Konstantinos Syrigos, John R. Penrod, Yong Yuan, Steven I. Blum, Faith E. Nathan, Xiaowu Sun, Alejandro Moreno‐Koehler, Fiona Taylor, Kenneth J. O’Byrne